5-isopropyl-3-(3-p-tolyl-ureido)-thiophene-2-carboxylic acid methyl ester

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-isopropyl-3-(3-p-tolyl-ureido)-thiophene-2-carboxylic acid methyl ester
• 英文别名: Methyl 5-isopropyl-3-(3-p-tolylureido)thiophene-2-carboxylate；methyl 3-[(4-methylphenyl)carbamoylamino]-5-propan-2-ylthiophene-2-carboxylate
• 化学式: C₁₇H₂₀N₂O₃S
• 分子量: 332.423
• InChiKey: XSEQAKHTJDAGQH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  95.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  甲基3-氨基-5-异丙基-2-噻吩羧酸酯 生成 5-isopropyl-3-(3-p-tolyl-ureido)-thiophene-2-carboxylic acid methyl ester
  参考文献：
  名称：

  p38 Kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas

  摘要：

  Inhibitors of the MAP kinase p38 are potentially useful for the treatment for osteoporosis, arthritis, and other inflammatory diseases. A series of thienyl, furyl, and pyrrolyl ureas has been identified as potent p38 inhibitors, displaying in vitro activity in the nanomolar range. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00574-6

文献信息

• Raf kinase inhibitors
  申请人：BAYER CORPORATION and ONYX PHARMACEUTICALS West Haven, CT and Richmond, CA, respectively

  公开号：US20010006975A1

  公开（公告）日：2001-07-05

  Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.

  通过使用替代尿素化合物和这些化合物本身，治疗由Raf激酶介导的肿瘤的方法。
• Raf Kinase Inhibitors
  申请人：WOOD Jill E.

  公开号：US20100063088A1

  公开（公告）日：2010-03-11

  Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.

  使用替代尿素类化合物治疗由Raf激酶介导的肿瘤的方法，以及这些化合物本身。
• RAF KINASE INHIBITORS
  申请人：Bayer Pharmaceuticals Corporation

  公开号：EP0986382B1

  公开（公告）日：2008-06-25
• EP0986382A4
  申请人：——

  公开号：EP0986382A4

  公开（公告）日：2001-04-11
• METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS GRP94
  申请人：Ferrone Soldano

  公开号：US20120148598A1

  公开（公告）日：2012-06-14

  Combinations of agents that have a synergistic effect for the treatment of a tumor are disclosed herein. These combinations of agents can be used to treat tumors, wherein the cells of the cancer express a mutated BRAF. Methods are disclosed for treating a subject diagnosed with a tumor that expresses a mutated BRAF. The methods include administering to the subject (1) a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds glucose regulated protein (GRP) 94; and (2) a therapeutically effective amount of a BRAF inhibitor. In some embodiments, the tumor is melanoma. In some embodiments the method includes selecting a subject with primary or secondary resistance to a BRAF inhibitor. In further embodiments, treating the tumor comprises decreasing the metastasis of the tumor. In additional embodiments, the BRAF inhibitor comprises PLX4032 or PLX4720.